SLN Relative Valuation
SLN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SLN is overvalued; if below, it's undervalued.
Historical Valuation
Silence Therapeutics PLC (SLN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -14.29. The fair price of Silence Therapeutics PLC (SLN) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：7.13
Fair
-7.51
PE
1Y
3Y
5Y
Trailing
Forward
-1.76
EV/EBITDA
Silence Therapeutics PLC. (SLN) has a current EV/EBITDA of -1.76. The 5-year average EV/EBITDA is -6.36. The thresholds are as follows: Strongly Undervalued below -17.84, Undervalued between -17.84 and -12.10, Fairly Valued between -0.62 and -12.10, Overvalued between -0.62 and 5.12, and Strongly Overvalued above 5.12. The current Forward EV/EBITDA of -1.76 falls within the Historic Trend Line -Fairly Valued range.
-1.76
EV/EBIT
Silence Therapeutics PLC. (SLN) has a current EV/EBIT of -1.76. The 5-year average EV/EBIT is -6.57. The thresholds are as follows: Strongly Undervalued below -16.77, Undervalued between -16.77 and -11.67, Fairly Valued between -1.47 and -11.67, Overvalued between -1.47 and 3.63, and Strongly Overvalued above 3.63. The current Forward EV/EBIT of -1.76 falls within the Historic Trend Line -Fairly Valued range.
22.23
PS
Silence Therapeutics PLC. (SLN) has a current PS of 22.23. The 5-year average PS is 27.14. The thresholds are as follows: Strongly Undervalued below -26.76, Undervalued between -26.76 and 0.19, Fairly Valued between 54.09 and 0.19, Overvalued between 54.09 and 81.04, and Strongly Overvalued above 81.04. The current Forward PS of 22.23 falls within the Historic Trend Line -Fairly Valued range.
-3.09
P/OCF
Silence Therapeutics PLC. (SLN) has a current P/OCF of -3.09. The 5-year average P/OCF is -22.18. The thresholds are as follows: Strongly Undervalued below -130.36, Undervalued between -130.36 and -76.27, Fairly Valued between 31.91 and -76.27, Overvalued between 31.91 and 86.00, and Strongly Overvalued above 86.00. The current Forward P/OCF of -3.09 falls within the Historic Trend Line -Fairly Valued range.
-3.19
P/FCF
Silence Therapeutics PLC. (SLN) has a current P/FCF of -3.19. The 5-year average P/FCF is -12.28. The thresholds are as follows: Strongly Undervalued below -38.78, Undervalued between -38.78 and -25.53, Fairly Valued between 0.98 and -25.53, Overvalued between 0.98 and 14.23, and Strongly Overvalued above 14.23. The current Forward P/FCF of -3.19 falls within the Historic Trend Line -Fairly Valued range.
Silence Therapeutics PLC (SLN) has a current Price-to-Book (P/B) ratio of 4.55. Compared to its 3-year average P/B ratio of 10.90 , the current P/B ratio is approximately -58.28% higher. Relative to its 5-year average P/B ratio of 16.85, the current P/B ratio is about -73.01% higher. Silence Therapeutics PLC (SLN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -18.10%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -12.60% , the current FCF yield is about -100.00% lower.
4.55
P/B
Median3y
10.90
Median5y
16.85
-24.28
FCF Yield
Median3y
-18.10
Median5y
-12.60
Competitors Valuation Multiple
The average P/S ratio for SLN's competitors is , providing a benchmark for relative valuation. Silence Therapeutics PLC Corp (SLN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -89.29%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SLN increased by 3.63% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -2.37K to -13.18K.
The secondary factor is the Revenue Growth, contributed -89.29%to the performance.
Overall, the performance of SLN in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Silence Therapeutics PLC (SLN) currently overvalued or undervalued?
What is Silence Therapeutics PLC (SLN) fair value?
How does SLN's valuation metrics compare to the industry average?
What is the current P/B ratio for Silence Therapeutics PLC (SLN) as of Dec 05 2025?
What is the current FCF Yield for Silence Therapeutics PLC (SLN) as of Dec 05 2025?
What is the current Forward P/E ratio for Silence Therapeutics PLC (SLN) as of Dec 05 2025?